


# Q3 FY26 QUARTERLY COMPANY CALL

30 April 2026

## Q3 FY26 KEY HIGHLIGHTS


- CurveBeam AI received purchase orders (POs) for **five (5) devices** in Q3 FY26, four (4) of which were HiRise™.
- Feedback on the HiRise™ application (**NMPA**) in China received. Requested supplemental data is being compiled and remains on track for clearance in the second half of the calendar year. Enables HiRise™ sales in China, a milestone payment, with further payments expected as sales orders follow.
- Continued work with WEGO Orthopaedics in **developing sales prospects to close following NMPA clearance**. Two of the purchase orders, in Q3FY26, were from WEGO for devices for training and supporting the technology transfer process.
- During the quarter, we met with a senior R&D Leader for the robotic surgery system on three occasions to **align on final clinical data for HiRise™ compatibility**. The next phase of clinical data collection with latest hardware and software upgrades.



HiRise™


## Q3 FY26 KEY HIGHLIGHTS

- Company has also made progress in advancing its total hip arthroplasty (THA) protocol for **one of the other four leading robotic surgery systems**. This work represents an important step in broadening partners with key robotic surgery systems.
- The Company has **received feedback on its FDA 510(k) application for the BMD module** for multi-detector computed tomography (MDCT) scans and is compiling the requested clinical review and supplemental analysis to support the FDA file. The targeted clearance of mid-year has moved to H2 CY26 for its initial product for multidetector CT scanners.
- Company announced **Patrick Fisher as a non-executive director**. US-based and a highly experienced global orthopaedic industry executive with more than 20 years of leadership experience across global medical device organisations. Currently President of Global Orthofix and has previously held senior leadership roles at Stryker and Wright Medical Group, across knee, hip, and foot & ankle



HiRise™


## Q3 FY26 PURCHASE ORDERS ANALYSIS



Receipts for Q3 FY26 were A\$1.4m, down 7% from the comparative quarter result in FY25 (A\$1.5m), & down 40% from A\$2.4m result in Q2 FY26. Carried A\$4.8m of PO's and receivables into Q3 and carries A\$5.4m into Q4.

CASH: Company notes the following in respect of quarters of cash:

- **Q3 close - cash of A\$4.3m & A\$5.4m of PO's & receivables carried into Q4.**
- Remain positive with the outlook for Q4 & prioritizing installations & collection of receipts from customers.
- Expects to be able to meet its business objectives based on current cash, ongoing management initiatives, with **access to a range of potential funding alternatives.**



HiRise™



InReach™



pedCAT®

# GREATER CHINA STRATEGY<sup>1</sup>

Partnership with Shandong Weigao Haixing subsidiary of Wego Orthopaedics

## Key terms

- For the sale, marketing, distribution, manufacturing, regulatory approval & IP for CVB's weight bearing CT & AI technology in China, Hong Kong, Macau & Taiwan (**Territories**)
- 10-year Exclusive licensing agreement for greater China
- JV Partner to make a \$10m equity investment in CVB:
  - 30-60 days of execution of license agreements - A\$4 million
  - HiRise™ units sold generating ~A\$4.6 million in sales - A\$1 million
  - HiRise™ units generating ~A\$18 million in sales - A\$2 million
  - Regulatory (MNPA) - A\$1 million
  - SkyRise™ & HiRise™ China manufacturing - A\$2 million

Shares to be issued at a \$0.405 per share





## Economics of HiRise™ (ASIA)

- JV Partner manufactures products
- JV Partner markets & sells products
  - US manufactured HiRise™
  - China manufactured HiRise™
- CVB earns royalties based on China produced HiRise™ /SkyRise™ scanner for greater Chinese sales
- **Seeking China FDA Approval (MNPA)**



---



## ENHANCED HIRISE™ PROJECT FOR ROBOTIC AIDED SURGICAL SYSTEMS




- In February and March 2026, the Company met again with the senior R&D leader responsible for supporting the assessment of HiRise™ for system compatibility.
- The Company is finalising the steps towards collecting expanded clinical data for submission to the vendor's R&D and Regulatory teams, whose reviews are anticipated to lead to the validation of HiRise™.
- A new post processing tool, scan reconstruction engine, and patient stabiliser will be released by the quality system in May to ensure we have a final protocol for validating readings.
- The company also made progress in advancing its total hip arthroplasty (THA) protocol for one of the other four leading robotic surgery systems. Development is underway, with continued collaboration supporting integration and optimization of the protocol for use with the system.

# BMD SAAS MDCT MODULE UPDATE

## Multidetector CT (MDCT)



HiRise



2<sup>nd</sup> Step  
clearance

- The Company received feedback including queries regarding the automated selection of region of interest, requiring some additional clinical reviews of the data.
- The requests are not a technical challenge, but will require more data, and may result in an expanded claim. Clearance is now targeted from mid-year to H2 CY26 for this initial product.
- The strategy remains a two-step regulatory process to achieve FDA clearance for the HiRise™ BMD module via a second FDA filing. This second step is planned to be a Special 510(k) filing for expanding the CT BMD module to the HiRise™ device

# DEFINITIONS

## CurveBeam AI's key metrics are defined and interpreted as follows:

- **Purchase order** – a signed purchase order (PO) for a CT scanner (device). The Company considers POs to be a key metric as it reflects actual sales at any given time.
- **Receipts from customers** – any cash consideration received from a customer by CurveBeam AI. This can include initial deposits required at the time of an order being placed.
- **Revenue** – Revenue is recognised after the device (e.g., HiRise™) is delivered, installed and training has been completed. Depending on the customer site requirements, there can be several months' delay from a signed purchase order to recognition of revenue. Thus, revenue may not be reflective of sales progress in each period.

The Company will report on POs and cash receipts in its Appendix 4C (quarterly) lodgments, while revenue will be reported in Appendix 4E (full year report) and Appendix 4D (half year report).